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Abstract 
Background: The clinical outcome of malaria depends on the delicate balance between pro‑inflammatory and 
immunomodulatory cytokine responses triggered during infection. Despite the numerous reports on characteriza‑
tion of plasma levels of cytokines/chemokines, there is no consensus on the profile of these mediators during blood 
stage malaria. The identification of acute phase biomarkers might contribute to a better understanding of the disease, 
allowing the use of more effective therapeutic approaches to prevent the progression towards severe disease. In the 
present study, the plasma levels of cytokines and chemokines and their association with parasitaemia and number 
of previous malaria episodes were evaluated in Plasmodium vivax‑infected patients during acute and convalescence 
phase, as well as in healthy donors.
Methods: Samples of plasma were obtained from peripheral blood samples from four different groups: P. vivax‑
infected, P. vivax‑treated, endemic control and malaria‑naïve control. The cytokine (IL‑6, IL‑10, IL‑17, IL‑27, TGF‑β, IFN‑γ 
and TNF) and chemokine (MCP‑1/CCL2, IP‑10/CXCL10 and RANTES/CCL5) plasma levels were measured by CBA or 
ELISA. The network analysis was performed using Spearman correlation coefficient.
Results: Plasmodium vivax infection induced a pro‑inflammatory response driven by IL‑6 and IL‑17 associated with 
an immunomodulatory profile mediated by IL‑10 and TGF‑β. In addition, a reduction was observed of IFN‑γ plasma 
levels in P. vivax group. A lower level of IL‑27 was observed in endemic control group in comparison to malaria‑naïve 
control group. No significant results were found for IL‑12p40 and TNF. It was also observed that P. vivax infection 
promoted higher levels of MCP‑1/CCL2 and IP‑10/CXCL10 and lower levels of RANTES/CCL5. The plasma level of IL‑10 
was elevated in patients with high parasitaemia and with more than five previous malaria episodes. Furthermore, 
association profile between cytokine and chemokine levels were observed by correlation network analysis indicating 
signature patterns associated with different parasitaemia levels.
Conclusions: The P. vivax infection triggers a balanced immune response mediated by IL‑6 and MCP‑1/CCL2, which 
is modulated by IL‑10. In addition, the results indicated that IL‑10 plasma levels are influenced by parasitaemia and 
number of previous malaria episodes.
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Background
Malaria is caused by a protozoan of the genus Plas-
modium and is responsible for high morbidity rates 
(besides the cases of mortality, especially among chil-
dren), resulting in serious impact on the socio-economic 
development in endemic regions. In the Brazilian Ama-
zon region, Plasmodium vivax is the main species caus-
ing malaria, being responsible for 82% of the cases [1]. 
Malaria is a complex disease involving genetic factors 
inherent to the parasite and to the host, geographical and 
environmental aspects that favour its occurrence and the 
difficulty of its eradication [2].
During infection, both the antibody-mediated and 
the cell-mediated immunity play an important role for 
achieving clinical immunity [3]. Several studies suggest 
that successful resolution of malaria infection depends 
on the ability of the host in inducing adequate levels of 
pro-inflammatory and regulatory cytokines during key 
stages of the infection. Thus, the fine-tuning between 
inflammatory and anti-inflammatory response appears 
to be a determinant factor in the clinical outcome of the 
disease [3–5].
Although the mechanisms involved in host immuno-
logical response during human malaria are still poorly 
understood, accumulating data suggest that malaria 
infection induces pro-inflammatory cytokines that elim-
inate the parasite or promote the removal of red blood 
cells infected by the parasite [6]. This response is sup-
pressed in turn by anti-inflammatory cytokines, and the 
clearance of remaining parasites as well as the preven-
tion of recrudescence or re-infection, are mediated by 
anti-parasite antibodies [6]. However, depending on fac-
tors such as genetic variability of host and parasite, age, 
number of infections and co-infections, the inflammatory 
response may be unregulated and, if excessive, it can lead 
to immunopathology.
Several studies have focused on the profile of plasma 
cytokines and chemokines in vivax malaria infection, 
comparing the repertoire of cytokines/chemokines elic-
ited between P. vivax and Plasmodium falciparum infec-
tion [7–11] and further association with disease severity, 
determined by clinical symptoms, or immunological 
profile after treatment with anti-malarial drugs [8–15]. 
Overall the profile of cytokine/chemokine production is 
still contradictory due to differences in study population, 
degree of endemicity in the region, among other factors, 
requiring further investigations.
The characterization of immune responses elicited 
during vivax malaria and correlations with the clinical 
symptoms can reveal important aspects for understand-
ing the pathogenesis of the disease and provide insights 
for the development of more effective vaccines and even 
new therapeutic approaches. Because of this, the plasma 
levels of pro- and anti-inflammatory cytokines and some 
chemokines were measured in this work during the acute 
phase of P. vivax naturally infected individuals. Samples 
were also obtained of some patients after anti-malarial 
drugs treatment to detect possible changes in the host 
immunological response after treatment and to identify 
biomarkers of active infection. Finally, analyses of cor-
relation among cytokines/chemokines levels, degree of 
parasitaemia and number of infections were performed 
to evaluate whether variations in clinical manifestations 
are associated with activated or suppressed cytokine/
chemokine networks.
Methods
Study participants and blood sample collection
Plasmodium vivax naturally infected individuals with 
uncomplicated symptomatic malaria (P. vivax group, 
n  =  75), P.vivax naturally infected individuals after 
25  days of treatment with chloroquine and primaquine 
(P. vivax-treated group, n  =  10) and non-infected sub-
jects with previous episodes of malaria (endemic control 
group, n = 10) were recruited at the Centro de Pesquisa 
em Medicina Tropical (Porto Velho, Rondônia, Brazil). 
In addition, 15 healthy donors (malaria-naïve control 
group) with no previous malaria exposure were recruited 
from a non-endemic area (Belo Horizonte, Minas Ger-
ais, Brazil). The demographic, parasitological and clini-
cal parameters of the subjects are shown in Table 1. The 
parasitological demonstration of P. vivax infection was 
performed by well-trained microscopists from the Cen-
tro de Pesquisa em Medicina Tropical using thick smears 
and it was further confirmed by nested polymerase chain 
reaction (PCR) as previously described [16]. Peripheral 
venous blood was collected in heparin-containing tubes 
and centrifuged to obtain plasma. Samples were stored 
at −80 °C until performing the cytokine and chemokine 
assays.
Cytokine and chemokine plasma levels assays
Measurements of IL-6, IL-10, IL-17, MCP-1/CCL2, 
RANTES/CCL5 and IP-10/IP-10/CXCL10 in the plasma 
samples were conducted using cytometric bead assay 
(CBA) (BD Biosciences, USA) according to manufactur-
er’s instructions. The data were collected using a FAC-
SCan flow cytometer (BD Biosciences, USA) and the 
results were analysed in FCAP Array software (Soft Flow). 
The limit of detection for each assay was: IL-6 = 2.4 pg/
mL, IL-10  =  4.5  pg/mL, IL-17  =  18.9  pg/mL, MCP-1/
CCL2  =  2.7  pg/mL, RANTES/CCL5  =  1.0  pg/mL and 
IP-10/CXCL10  =  2.8  pg/mL. The upper-range lim-
its of detection for the assays were 5000.0  pg/mL for 
chemokines (MCP-1/CCL2, RANTES/CCL5 and IP-10/
CXCL10), and 2500.0  pg/mL for cytokines (IL-6, IL-10 
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and IL-17) detection. Dilution of samples was performed 
whenever necessary to ensure the obtained values fell 
within the range of the generated standard curve.
Enzyme-linked immunosorbent assay (ELISA) was 
performed for the measurement of IL-12p40, IL-27, IFN-
γ, TNF and TGF-β (R&D Systems, USA), according to 
manufacturer’s instructions. Biotin-labeled antibodies 
were used for detection and the assay was revealed with 
streptavidin-HRP (Amersham Biosciences, USA) using 
OPD (o-Phenylenediamine dihydrochloride) substrate 
system (Sigma, USA). The colorimetric reaction was read 
using an automated ELISA microplate reader (Versa-
max, Molecular Devices, USA) at 492 nm. The cytokine 
concentration was calculated from the standard curve 
using seven-parameter curve fitting software (SOFT-
maxPro 5.3, Molecular Devices). The limit of detection 
for each assay was 156.0  pg/mL for IL-27, 62.5  pg/mL 
for IL-12p40, 31.2 pg/mL for TGF-β, and15.6 pg/mL for 
IFN-γ and TNF. The upper-range limits of detection for 
the assays were 10,000.0 pg/mL for IL-27, 4000.0 pg/mL 
for IL-12p40, 2000.0  pg/mL for TGF-β, and 1000.0  pg/
mL for IFN-γ and TNF. Dilution of samples was per-
formed whenever necessary to ensure the obtained val-
ues fell within the range of the generated standard curve.
Statistical analysis
Statistical analyses were conducted using the Prism soft-
ware 5.0 for Windows (GraphPad Inc, USA). Initially, 
Grubb’s test was applied to detect possible outliers and 
the Kolmogorov-Smirnoff test was used to verify the 
data distribution. Comparisons among groups were per-
formed using Kruskal–Wallis test followed by Dunn’s 
Post-hoc test or Mann–Whitney U test. The paired t test 
and Wilcoxon test were also applied, according to data 
distribution. Statistical differences were considered sig-
nificant when p values were less or equal to 0.05. Results 
were corrected for multiple comparisons as needed.
Correlation networks were generated by the analysis 
of relationship among cytokine and chemokine plasma 
level datasets. Initially, pair-wise Spearman correlation 
coefficients were calculated using a scientific computing 
library (SciPy) and python programming language. Along 
with the Spearman rank-order correlation coefficient, the 
p value to test for non-correlation was evaluated using 
p ≤ 0.05 as a cut-off. The correlation strength was sepa-
rated into three ranges: weak (0.2 ≤  r  <  0.5), moderate 
(0.5 ≤ r < 0.7) and strong (0.7 ≤ r ≤ 1.0).
Results
Plasmodium vivax infection triggers a marked 
pro‑inflammatory cytokine response
The circulating levels of pro-inflammatory cytokines 
such as IL-6, IL-17, IL-12p40, and TNF were prominent 
in P. vivax naturally infected individuals when compared 
to plasma levels observed in other groups (malaria-naïve, 
endemic and P. vivax-treated) (Fig.  1a–d), although sig-
nificant differences to control groups were observed only 
for IL-6 and IL-17 (p  <  0.0001 and p =  0.0051, respec-
tively) (Fig.  1a, b). Conversely, the P. vivax infection 
resulted in a significant reduction of IFN-γ plasma levels 
when compared to control groups (p < 0.0001) (Fig. 1e), 
with circulating levels of IFN-γ detected in only 20% of 
the samples from P. vivax group.
After treatment, production of IL-6, IL-12p40, TNF 
and IFN-γ were restored to baseline levels (p < 0.001 for 
IL-6 and p < 0.05 for IFN-γ, only), in contrast to plasma 
levels of IL-17, which were similar to those presented by 
infected individuals before treatment. In addition, it was 
also observed a significant decrease of IL-6 after treat-
ment during a paired analysis (Fig. 1f ).
Table 1 Demographic, parasitological and  symptomato-
logical parameters of the study population
The parasitaemia and symptoms in the P. vivax‑treated group refers to acute 















27 (19–35) 38 (21–49) 37 (20–80) 42 (21–50)
Gender [n(%)]
 Male 10 (66.7) 6 (60.0) 57 (76.0) 6 (60.0)
 Female 5 (33.3) 4 (40.0) 18 (24.0) 4 (40.0)
Parasitaemia (parasites/mm3), [n = (%)]
 ≤500 – – 34 (45.3) –
 501–10,000 – – 26 (34.7) –
 10,001–100,000 – – 8 (10.7) –
 Without informa‑
tion
– – 7 (9.3) –
Nº of previous malaria episodes [n(%)]
 First malaria – 3 (30.0) 10 (13.3) 1 (10.0)
 ≤5 – 2 (20.0) 24 (32) 2 (20.0)
 >5 – 5 (50.0) 33 (44.0) 6 (60.0)
 Without informa‑
tion
0 (0.0) 8 (10.7) 1 (10.0)
Symptoms [n(%)]
 Fever – – 66 (97.1) –
 Headache – – 66 (97.1) –
 Myalgia – – 61 (89.7) –
 Chills – – 60 (88.2) –
 Sweating – – 51 (75.0) –
 Arthralgia – – 49 (72.1) –
 Nausea – – 36 (52.9) –
 Vomiting – – 20 (29.4) –
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Higher levels of IL‑10 and TGF‑β were also induced 
during Plasmodium vivax infection
Production of IL-10 was only observed in the P. vivax 
group, being present in 94.4% of the plasma samples 
(median  =  186.1  pg/mL). After treatment, the IL-10 
level returned to basal levels, equivalent to levels 
observed in control groups (p < 0.001) (Fig. 2a). Similar 
result was observed for the paired analysis comparing 
the cytokine levels before and after treatment (Fig. 2b). 
Moreover, samples from P. vivax group presented sig-
nificant higher levels of TGF-β (median  =  42.8  pg/
mL) when compared to malaria-naïve control group 
(median  =  10.3  pg/mL) (p  =  0.0353) but similar pro-
duction of this cytokine when compared to endemic 
control (median  =  48.9  pg/mL) and P. vivax-treated 
(median = 43.7 pg/mL) groups (Fig. 2c). No significant 
differences in the TGF-β production was observed for 
the paired analysis comparing the cytokine level before 
and after treatment (p = 0.7344).
IL‑27 in vivax malaria
IL-27 is a pleiotropic cytokine that can induce either a 
pro-inflammatory or immunoregulatory response. The 
production of IL-27 was reduced in individuals living 
in endemic areas (endemic control, P. vivax-infected 
and P. vivax-treated individuals). However, significant 
differences were observed only between the malaria-
naïve control (median =  1257.0  pg/mL) and endemic 
control (median =  105.3  pg/mL) groups (p =  0.0389, 
Fig. 3).
Plasmodium vivax infection induced higher levels 
of MCP‑1/CCL2 and IP‑10/CXCL10 and lower levels 
of RANTES/CCL5
The plasma levels of MCP-1/CCL2 were increased 
in P. vivax-infected individuals (median  =  770.6  pg/
mL) when compared to malaria-naïve control 
group (median  =  97.3  pg/mL) and endemic con-
trol group (median  =  76.0  pg/mL) (Fig.  4a), with fur-
ther re-establishment to basal levels after treatment 
(median  =  104.5  pg/mL) (p  <  0.0001). Plasma samples 
from P. vivax-infected donors also presented higher lev-
els of IP-10/CXCL10 in comparison to control groups 
(p  <  0.0001) but, similarly to MCP-1/CCL2, the IP-10/
CXCL10 plasma level in treated individuals presented 
a baseline production that is equivalent to control indi-
viduals (p  <  0.001) (Fig.  4b). On the other hand, lower 
RANTES/CCL5 plasma levels were observed in individ-
uals with P. vivax infection when compared to endemic 
control group (p = 0.0010) (Fig. 4c).
Fig. 1 Inflammatory cytokine plasma levels. Comparative analysis of IL‑6 (a), IL‑17 (b), IL‑12p40 (c), TNF (d) and IFN‑γ production among malaria‑
naïve control group (n = 15), endemic control group (n = 10), P. vivax group (n = 75) and P. vivax‑treated group (n = 10) were performed using 
Kruskal–Wallis test followed by Dunn Post‑hoc. The dotted lines (—) represent the detection limit of the assay. IL‑6 levels in acute‑phase and conva‑
lescence period from P. vivax‑infected patients (e) was compared between P. vivax group (n = 10) and P. vivax‑treated group using Paired t‑test or 
Wilcoxon test, according to data distribution. A p value <0.05 was considered significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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The comparison between plasma levels for both 
MCP-1/CCL2 and IP-10/CXCL10, before and after treat-
ment (paired analysis), also showed significant differ-
ences (p = 0.0048 and p = 0.0012, respectively) (Fig. 4d, 
e). Despite the absence of significant result between P. 
vivax group and P. vivax-treated group due probably to 
high variability of chemokine levels and differences of 
sample number, a significant increase was observed in 
the plasma level of RANTES/CCL5 in the paired t-test 
after the treatment when following the same individuals 
(Fig. 4f ).
IL‑10 plasma levels were associated with parasitaemia 
and number of previous malaria episodes
Plasmodium vivax-infected patients were separated into 
two groups according to parasitaemia:  ≤500 parasites/
cu mm denominated as low parasitaemia and >501 par-
asites/cu mm as high parasitaemia (Fig.  5a). Patients 
with low parasitaemia presented reduced levels of IL-10 
(median =  56.2  pg/mL) in comparison to patients with 
high parasitaemia (median = 366.1 pg/mL) (p < 0.0134). 
Furthermore, higher number of previous malaria epi-
sodes was associated with higher IL-10 plasma levels 
(p < 0.0242) (Fig. 5b).
Immune response mediators established a complex 
network during Plasmodium vivax infection
During P. vivax infection, the triggering of several plasma 
mediators might result in a complex interaction network, 
which may render a weak, moderate or strongly correla-
tion among themselves. The network profiles observed 
in the P. vivax group, as well as the sub-groups classified 
according to the parasite load, are shown in Fig. 6. Inter-
estingly, high parasitaemia network includes practically 
all correlation observed in the network of all infected 
patients (Fig. 6a) highlighting the importance of parasite 
numbers to host immune stimulation. The correlation 
network between plasma mediators is less connected in 
low (Fig. 6b) than high parasitaemia (Fig 6c).
Plasmodium vivax-infected patients presented a strong 
correlation between IL-6 and MCP-1/CCL2 (r  =  0.82, 
p  <  0.0001). Furthermore, moderate correlations were 
observed between IL-6 and IL-10 (r = 0.60, p < 0.0001) 
and between IL-12p40 and TNF-a (r = 0.54, p < 0.0001). 
Several weak correlations were observed among other 
cytokines and chemokines (Fig.  6a). Plasmodium vivax 
patients were further separated into two sub-groups 
according to parasitaemia: low (≤500  parasites/cu  mm) 
and high (>501 parasites/cu mm). Patients with low para-
sitaemia presented moderate/strong correlations among 
inflammatory mediators (IL-6/IFN-γand MCP-1/CCL2). 
On the other hand, only a weak correlation between 
Fig. 2 Regulatory cytokine plasma levels. Comparative analysis of IL‑10 (a total production; b paired analysis between infected and treated individu‑
als) and TGF‑β among malaria‑naïve control group (n = 15), endemic control group (n = 10), P. vivax group (n = 75) and P. vivax‑treated group 
(n = 10) were performed using Kruskal–Wallis test followed by Dunn Post‑hoc. A p value <0.05 was considered significant. The dotted lines (—) 
represent the detection limit of the assay. Paired analysis was performed between P. vivax group (n = 10) and P. vivax‑treated group using Paired 
t‑test or Wilcoxon test, according to data distribution. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 3 Plasma levels of IL‑27 during vivax malaria. Comparative analy‑
sis of IL‑27 among malaria‑naïve control group (n = 15), endemic 
control group (n = 10), P. vivax group (n = 75) and P. vivax‑treated 
group (n = 10) were performed using Kruskal–Wallis test followed by 
Dunn Post‑hoc. A p value <0.05 (*) was considered significant. The 
dotted lines (—) represent the detection limit of the assay
Page 6 of 10Hojo‑Souza et al. Malar J  (2017) 16:42 
IL-6/IL-10 and IL-12p40/TNF was observed in this sub-
population (Fig.  6b). Furthermore, patients with high 
parasitaemia presented moderate correlations between 
IL-6 and IP-10/CXCL10 (r  =  0.56, p  <  0.001), IL-10 
and MCP-1/CCL2 (r  =  0.62, p  <  0.001), MCP-1/CCL2 
and IP-10/CXCL10 (r =  0.55, p  <  0.001) and IL-6/TNF 
(r = 0.55, p < 0.001) (Fig. 6c).
Discussion
While some studies have investigated cytokines/
chemokines plasma levels during P. vivax infection [7–15, 
17–19], there is still no agreement regarding the produc-
tion of cytokines/chemokines and protection. It is well 
established that a pro-inflammatory response is required 
for parasite elimination, but an immunomodulatory 
Fig. 4 Chemokine plasma levels. Comparative analysis of MCP‑1/CCL2 (a), IP‑10/CXCL10 (b), and RANTES/CCL5 (c) production among malaria‑naïve 
control group (n = 15), endemic control group (n = 10), P. vivax group (n = 75) and P. vivax‑treated group (n = 10) were performed using Kruskal–
Wallis test followed by Dunn Post‑hoc. The dotted lines (—) represent the detection limit of the assay. Levels of MCP‑1/CCL2 (D), IP‑10/CXCL10 (e) 
and RANTES/CCL5 (f) in acute‑phase and convalescence period from P. vivax infected patients were determined from P. vivax group (n = 10) and 
P. vivax‑treated group using Paired t‑test or Wilcoxon test, according to data distribution. A p value <0.05 was considered significant. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001
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response is also needed to prevent immunopathology 
[6]. In the present study, it was shown that P. vivax infec-
tion induced increased levels of IL-6 and, after treatment, 
the plasma levels were restored. These findings were in 
agreement with previous studies during acute phase [11, 
15, 17, 18] although the controversial data in the litera-
ture with reduction [10, 14] or increase [11] of IL-6 after 
the treatment, which might be attributed to convales-
cence period range (7–45 days) in the different studies [8, 
10, 11, 13, 14].
Higher levels of some pro-inflammatory mediators such 
as IL-6, MCP-1/CCL2 and IP-10/CXCL10 were observed 
in P. vivax-infected patients, which were re-established 
after anti-malarial treatment, suggesting that the parasite 
infection triggered an inflammatory response. Concomi-
tantly, it seems to be a consensus that P. vivax infection 
induces higher levels of IL-10 during acute phase of vivax 
malaria [7, 8, 10–13, 15, 17–19] and that the cytokine 
levels were restored to baseline after treatment [8, 10, 
11, 14]. Indeed, a previous study demonstrated that 
CD4+CD25+ T cells producing IL-10 play a significant 
role during Plasmodium infection, possibly controlling 
the pro-inflammatory cytokines IFN-γ and TNF [6]. Of 
note, previous studies also demonstrated the increased 
number of circulating Treg cells (CD4+CD25+Foxp3+) 
during P. vivax infection [20, 21]. Regarding the asso-
ciation between IL-10 plasma levels with parasitaemia 
and number of previous malaria episodes, in the pre-
sent study, it was observed higher IL-10 plasma levels in 
patients with high parasitaemia (>501 parasites/cu mm) 
and with more than five previous malaria episodes. 
Similar result was observed for the association with par-
asitaemia, but not with number of previous malaria epi-
sodes [18]. The significance of IL-6 and IL-10 has been 
highlighted during vivax  malaria. High levels of these 
cytokines were observed in uncomplicated cases [18, 
22], while low IL-6 levels were observed in patients with 
complicated malaria [22]. In addition, a positive correla-
tion between IL-6 and IL-10 has also been observed in P. 
vivax infection [10, 18, 22]. Likewise, in the present study 
correlation analysis between IL-6 and IL-10 demon-
strated a positive correlation (r = 0.60) in P. vivax group, 
suggesting the acquisition of a more immunomodulatory 
profile. The association between IL-10 plasma levels and 
high parasitaemia could reflect a self-regulation mecha-
nism to protect the excessive inflammatory response 
because of high antigen stimulation.
During acute episode of vivax malaria, several stud-
ies have reported high plasma levels of IFN-γ [7, 10, 12, 
15, 19]. In the present study, IFN-γ plasma levels were 
only observed in 20% of P. vivax patient samples. On the 
other hand, the majority of patients of this group pre-
sented higher production of IL-17. However, reports on 
IL-17 production in the human malarial infection are 
poorly described [9, 11] and further investigations are 
required. It is important to highlight that IL-17 may be 
produced by macrophages, dendritic cells, NK, NKT, 
γdT cells, CD8+ and Th17 [23, 24] and the source of this 
cytokine during P. vivax infection needs more investiga-
tion. A previous study showed that CD4+ T cells pro-
ducing IL-17 were increased during vivax malaria [25]. 
The higher plasma levels of TGF-β and IL-6 in the acute 
phase could suggest the induction of IL-17, since naïve 
CD4+ T cells require stimulation by IL-6 and TGF-β, 
and possibly IL-1b, to differentiate in Th17 and to secrete 
IL-17 [23, 26, 27]. Th17 cells induced by IL-6 and TGF-β 
also produce IL-10, presenting a regulatory function [28]. 
It is important to highlight that the low levels of IFN-γ 
observed in P. vivax group could contribute to high levels 
Fig. 5 IL‑10 plasma levels and their associations. a Parasitaemia: 
high vs low number of parasites. Comparison between high (>500 
parasites/cu mm, n = 33) and low (≤500 parasites/cu mm, n = 32) 
number of parasites was performed using Mann–Whitney test. b 
Number of previous malaria episodes. Comparisons among first 
malaria (n = 10), ≤5 episodes (n = 24) and >5 episodes (n = 32) 
were performed using Kruskal–Wallis test followed by Dunn Post‑hoc. 
A p value <0.05 was considered significant. *p < 0.05. The dotted lines 
(—) represent the detection limit of the assay
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of IL-17 once IFN-γ negatively regulates the generation 
of IL-17-producing cells [29].
Despite the high TGF-β plasma levels observed during 
P. vivax infection, there was no consensus about these 
findings [8, 10, 15]. TGF-β is a potent inductor of Treg 
cells [30], which may have contributed to the high IL-10 
plasma levels observed. Although high IL-17 plasma lev-
els were observed in P. vivax group, only a weak nega-
tive correlation was detected between IL-17 and TGF-β 
by the network analysis approach. This connection was 
also found in low parasite load sub-group. Therefore, the 
IL-17 and TGF-β roles during P. vivax infection require 
additional investigations. Regarding IL-12p40 and TNF, 
no significant results were observed in the present study. 
However, differences in literature findings occur for both 
cytokines in acute phase [7, 8, 10–13, 15, 17–19] and 
convalescence period [8, 10, 11, 13, 14].
IL-27 is a pleiotropic cytokine with both pro- and anti-
inflammatory actions. This cytokine is a potent inhibitor 
of Th17 cell development and of IL-17 induction [31, 32]. 
In the present study, low IL-27 levels were observed in 
endemic control group compared to malaria-naïve con-
trol group. However, no difference was observed regard-
ing to IL-17 between the control groups. In children 
infected with P. falciparum, IL-27 plasma levels were 
decreased during uncomplicated malaria in compari-
son to endemic control group. This reduction was more 
accentuated in severe cases [33]. Thus, the IL-27 role in 
vivax malaria needs further investigation.
MCP-1/CCL2, known as Monocyte Chemoattract-
ant Protein-1, is a powerful attractant of monocytes, 
T cells and dendritic cells to inflammatory sites. This 
chemokine is produced by several cell types, such 
as  epithelial, endothelial, smooth muscle, fibroblasts, 
astrocytes, monocytes, and microglial cells, and can be 
induced by TNF, IL-1 and endotoxins [34]. In the present 
study, high plasma levels of MCP-1/CCL2 were observed 
during P. vivax infection. Similar result was previous 
described during P. vivax infection [7]. The pro-inflam-
matory IL-6 cytokine induced the mRNA expression and 
MCP-1 secretion by peripheral blood mononuclear cells 
[35].  During blood stage of P. vivax infection both IL-6 
and MCP-1/CCL2 were significantly elevated. The  net-
work analysis revealed a strong correlation between IL-6 
and MCP-1/CCL2, regardless of parasite load, suggest-
ing that these mediators were induced by the infection 
itself. These findings support the hypothesis that IL-6 and 
MCP-1/CCL2 pathway plays a central role in response 
to P. vivax infection. Interestingly, the network analyses 
for the high and low parasitaemia groups have shown 
that individuals with high parasitaemia exhibit moder-
ate/strong correlation between IL-6/IL-10 and MCP-1/
CCL2. However, patients with low parasitaemia exhib-
ited weak correlation between IL-6 and IL-10, losing the 
Fig. 6 Plasma mediators network. Correlations among 11 mediators during P. vivax infection were plotted in network graphs. Each circle represents 
a cytokine or chemokine and the connecting lines represent significant correlations between two mediators. Solid and dotted lines, respectively, 
represent positive and negative correlations. The line thickness represents the significance degree. a P. vivax group (n = 73). b P. vivax sub‑group with 
low parasitaemia (≤500 parasites/cu mm) (n = 34). c P. vivax sub‑group with high parasitaemia (> 500 parasites/cu mm) (n = 34). The correlation 
analyses were evaluated by Spearman correlation test. A p value <0.05 was considered significant
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interaction between IL-10 andMCP-1/CCL2. These data 
associated with the positive correlation between IL-6/
IFN-γ reinforce the significance of the IL-6/MCP-1/
IFN-γ axis in controlling parasitaemia, which could con-
tribute to the lower parasite load observed.
IP-10/CXCL10 (IFN-inducible protein 10) is another 
chemokine that is induced by IFN-γ [36] as well as by 
IL-17 [37] in different cell types. This chemokine is 
involved in inflammatory processes, being capable of 
attracting macrophages, dendritic cells, NK cells and 
activated CD4+ and CD8+ T cells towards inflamed tis-
sues [36]. In the present study, P. vivax  infected patients 
presented elevated IP-10/CXCL10 plasma levels, but only 
weak positive correlation with IFN-γ. No correlation was 
observed between IP-10/CXCL10 and IL-17, although 
both mediators were elevated during P. vivax infection. 
However, when patients were separated according to 
the parasite load, this connection was lost, and moder-
ate correlation was established between IP-10/CXCL10 
and IL-6, only in patients with high parasitaemia. In  P. 
falciparum  infection, IP-10/CXCL10 has been identified 
as biomarker (in serum and cerebrospinal fluid) associ-
ated with elevated risk of fatal cerebral malaria [38]. On 
the other hand, higher IP-10/CXCL10 plasma levels, as 
well as IFN-γ and IL-10, were observed in vivax malaria 
patients with mild anaemia in comparison to no anaemia 
[12].
RANTES/CCL5, known as Regulated upon Activation 
Normal T cell Expressed and Secreted, is an inflamma-
tory chemokine attractant of T cells, basophils, eosino-
phils, and dendritic cells to inflammatory site [39]. 
RANTES/CCL5 is produced predominantly by CD8+ 
T cells, epithelial cells, fibroblasts, and platelets [40]. 
In children infected by  falciparum  malaria low mRNA 
and RANTES protein levels were associated with severe 
malaria [41]. Lower RANTES levels were also found 
in children with cerebral malaria and a strong positive 
correlation was verified between RANTES levels and 
platelets count [42]. In the present study, vivax malaria 
patients have shown significant low RANTES/CCL5 lev-
els, but just weakly associated with IL-6, IL-12p40, IFN-γ 
or MCP-1/CCL2. The lower levels of RANTES/CCL5 
could be explained by the CD8+ T cells reduction [43–
45] and thrombocytopaenia [8, 10, 11, 44–46] observed 
during vivax malaria.  A study carried out with children 
infected with P. falciparum observed an association 
between thrombocytopaenia and lower RANTES plasma 
levels [47].
Conclusion
Taken together, the multiple analyses performed in the 
present study allowed the identification of an immuno-
logical signature from plasma mediators associated with 
P. vivax acute infection. IL-6, MCP-1/CCL2 and IL-10 
could be recognized as biomarkers of acute phase of P. 
vivax infection. These results provide new insights into 
the complex relationship among mediators that are trig-
gered during P. vivax clinical malaria.
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